IGF-1 and Growth Hormone: Why More Is Not Younger

TL;DR: IGF-1 is the standard blood marker for growth-hormone activity, and it is one of the places where the longevity evidence and the anti-aging marketplace point in opposite directions. Growth hormone tells the liver to make IGF-1, which drives growth, muscle, and repair and sits at the center of the body's nutrient-and-growth signaling, the same network that caloric restriction and rapamycin turn down. Across species, turning that signal down tends to go with a longer life: mice bred with very low IGF-1 live around 50 percent longer, and people with a rare growth-hormone-receptor defect that leaves IGF-1 very low almost never develop diabetes or cancer. In the general population, a higher IGF-1 carries a modest but consistent rise in the risk of prostate, breast, and colorectal cancer. Put together, that makes a higher IGF-1 a growth signal rather than a badge of youth, and it means the anti-aging clinics selling growth hormone and peptides to push IGF-1 up have the direction backwards, on evidence that does not support benefit, with clear harm, and, for growth hormone used against aging, against the law. The honest complication is that lower is not the goal either: in older adults a very low IGF-1 travels with frailty, fractures, cognitive decline, and heart disease, so mortality follows a U-shape with risk at both ends. The sensible target is a healthy mid-range for your age, reached through strength training, sleep, adequate protein, and metabolic health, rather than a drug driving the number in either direction.

What is IGF-1, and why do people track it?

Growth hormone is released in pulses from the pituitary gland, mostly at night, and it acts mostly by telling the liver to produce insulin-like growth factor 1, or IGF-1. IGF-1 carries out most of what growth hormone is credited with, building muscle and bone, repairing tissue, and, in childhood, driving height. Because growth hormone comes in bursts that are hard to catch on a single blood draw while IGF-1 stays fairly steady through the day, IGF-1 is the practical blood proxy for how active the whole growth-hormone axis is.

The deeper reason IGF-1 shows up on longevity panels is where it sits in the body's wiring. It signals through a receptor closely related to the insulin receptor, feeding into the same growth-and-nutrient network, the insulin, IGF, and mTOR pathways, that senses how well-fed the body is and decides whether to grow or to maintain and repair. That network is the one that caloric restriction and the drug rapamycin turn down to extend life in laboratory animals. IGF-1 is a pro-growth input to it, which is why it declines with age and why it draws so much interest as a dial someone might want to turn. The question this article is really about is which way to turn it.

Why do longevity scientists say less IGF-1 can mean more life?

This is the part that surprises people, because it runs against the intuition that more growth hormone means a younger body. Across the animal kingdom, dialing the growth-hormone and IGF-1 signal down tends to lengthen life. Mice bred to lack normal growth-hormone signaling, with very low IGF-1, live around 50 percent longer than their normal littermates, one of the largest single-gene lifespan extensions ever shown in a mammal.² The pattern holds in worms and flies too, which is why researchers treat reduced growth signaling as one of the most conserved levers on aging.

The human echoes are striking. In a mountain population in Ecuador, a group of people carry a defect in the growth-hormone receptor, called Laron syndrome, that leaves them short and with very low IGF-1. Followed over decades, they almost never develop diabetes, despite frequent obesity, and they have had strikingly little cancer compared with their unaffected relatives.¹ At the other end of the lifespan, studies of people who reach 100 have found an enrichment of gene variants that blunt IGF-1's signal,³ and among the very old, women with a below-median IGF-1 have lived longer than those above it.¹¹ The through-line, the same one behind caloric restriction and rapamycin, is that a body doing less growing appears to spend more of its budget on maintenance and repair, which over a lifetime seems to slow the wear of aging. The honest boundary on this is that the dramatic versions come from short-lived animals and rare human conditions, and they do not by themselves tell a healthy person with an ordinary IGF-1 to suppress it, a point the U-shape below makes concrete.

Does a high IGF-1 raise cancer risk?

The cancer link is the most practically important reason not to chase IGF-1 upward, and it needs stating with care, because the effect is consistent but modest. IGF-1 is a growth factor for many tissues, so it is biologically intuitive that more of it would nudge the odds of cancer up, and the population data bear that out for the common hormone-and-growth-sensitive cancers.

A pooled analysis of 17 prospective studies found that women in the highest fifth of IGF-1 had roughly 28 percent higher odds of breast cancer than those in the lowest fifth, an association confined to the estrogen-receptor-positive type.⁴ For prostate cancer, a similar pooled analysis put the highest-versus-lowest odds around 38 percent higher.⁵ And in a very large UK cohort tracking many cancers at once, each step up in IGF-1 raised the risk of breast, prostate, and colorectal cancer by roughly 8 to 11 percent per increment.⁶ These are repeatable associations, and for breast and colorectal cancer genetic studies support a partly causal role. The discipline is to hold their size with care: risk estimates in the range of 1.1 to 1.4 mean a meaningfully raised risk across a population, rather than a diagnosis or a doubling, so the right reading is that pushing IGF-1 high with drugs adds cancer risk without a proven upside, rather than that a naturally mid-range IGF-1 is dangerous.

Should I try to get my IGF-1 as low as possible?

No, and this is the mirror-image mistake to avoid. It is tempting to read the longevity data as "lower is always better" and go the other way, starving protein or otherwise driving IGF-1 to the floor. The evidence does not support that, because the relationship between IGF-1 and dying is U-shaped: risk rises at both ends.

A meta-analysis of nearly 15,000 people found that both a low and a high IGF-1 carried higher all-cause mortality than the middle of the range, with low IGF-1 tied to more cardiovascular death and high IGF-1 to more cancer death.⁷ In older adults the low end is its own hazard: a very low IGF-1 travels with frailty, muscle loss, thinning bone and fractures, cognitive decline, and cardiovascular events. Growth signaling is more than a pro-aging nuisance; it is also what keeps muscle and bone maintained, and too little of it in later life is a problem in its own right. So the goal is not a race to the bottom. It is a healthy mid-range appropriate to your age, and an IGF-1 that is markedly high or markedly low is a reason to look for a cause rather than a number to force.

What about growth hormone and peptide anti-aging clinics?

Here is where the marketplace and the evidence part company most sharply, and where being clear protects both your health and your wallet. The anti-aging use of growth hormone traces back to a small 1990 study in which older men given the hormone gained lean mass and lost fat over six months.⁸ That single result launched an industry, but the body-composition change was the whole of it, and even there blood pressure and blood sugar rose. When the field pooled the later controlled trials, the verdict was blunt: in healthy older people, growth hormone produces small changes in body composition, no proven gain in strength, function, or bone, and a much higher rate of side effects, including swelling, joint pain, carpal tunnel, breast enlargement in men, and a drift toward diabetes.⁹ It cannot be recommended as an anti-aging therapy.

Two more facts settle it. Growth hormone used against aging is not a legal gray area in the United States; federal law makes it a crime to distribute growth hormone for anything other than a short list of approved medical conditions, and writing the prescription counts as distributing it. And nature runs the high-growth-hormone experiment for us in acromegaly, the disease of chronic growth-hormone excess, where people develop heart disease, diabetes, arthritis, and a roughly doubled risk of colon cancer, and die earlier on average until the excess is corrected. Living with high growth hormone for years is the opposite of rejuvenation. The newer wave of clinics has moved to peptides, sermorelin, ipamorelin, CJC-1295, and the oral compound MK-677, that coax the body to make more of its own growth hormone. None of these is approved for anti-aging or longevity, their best long-term human study raised IGF-1 while worsening blood sugar and delivering no functional benefit, and their compounding status is an unsettled regulatory question rather than a stamp of approval. The direction they push, IGF-1 upward, is the direction the longevity evidence argues against.

What raises and lowers IGF-1, and the protein tension?

The levers on IGF-1 are mostly the ordinary ones. Protein intake raises it, resistance exercise and deep sleep support it, and it falls with caloric restriction, protein restriction, fasting, and age. This is where a true tension lives, and it is worth thinking through rather than resolving with a slogan. A well-known analysis found that among adults aged 50 to 65, a high-protein diet was linked to substantially higher cancer and overall mortality, an effect that ran mostly through IGF-1, so in midlife the growth-versus-longevity trade is present and favors moderation.¹⁰ But the same study found the relationship reversed after about 65, where higher protein went with lower mortality.

That reversal is the practical key. Older adults lose muscle and bone, and defending against that loss requires adequate protein and resistance training, even though both raise IGF-1. Deliberately starving protein to suppress IGF-1 in an older person trades a small theoretical gain against a serious risk of frailty and fracture, which the U-shape says is the wrong trade. The reasonable frame is that in youth and midlife the growth-versus-longevity tension favors not overdoing growth signals, plant-forward eating, and staying lean and insulin-sensitive, while after around 65 the balance tips toward protecting muscle and bone with enough protein and training. In neither phase does the evidence point toward a drug to move the number.

How should I read my IGF-1 on a longevity panel?

Read it as a growth signal rather than a youth score. A high IGF-1 is not a sign that your body is biologically younger; if anything, sustained high growth signaling tracks with cancer and metabolic risk, so the instinct to celebrate a high number is backwards. Interpret it against your age and sex, since IGF-1 falls with age, and against the U-shape, where both a very high and a very low value carry risk.

The practical takeaways follow from that. Do not chase a high IGF-1 with growth hormone or peptides, which is unproven, risky, and in the case of growth hormone illegal. Do not chase it to the floor either, because too low is its own hazard, particularly in later life. Aim instead for a healthy mid-range through the levers that improve everything else at once, strength training, sleep, adequate but not maximal protein, and metabolic health. And treat a markedly abnormal value as a prompt to look for a reason: a very high IGF-1 warrants checking for a growth-hormone-producing tumor, and a very low one warrants a look at nutrition, pituitary function, and overall illness, rather than an attempt to optimize the number with a prescription.

Guidance from the Clinic

"IGF-1 is one of the numbers where the longevity crowd and the anti-aging clinics want opposite things, and the clinics have it backwards. When someone shows me a panel and asks how to get their IGF-1 higher, I slow that down, because the human evidence links higher growth signaling to more cancer, and the growth-hormone and peptide route is unproven, risky, and in the case of growth hormone for aging, illegal. But I am just as careful with the person who read that low IGF-1 means longer life and started cutting protein to drive it down. The mortality curve is U-shaped, and in an older adult a low IGF-1 comes with frailty and fractures, which is not the trade I want. What I do is unglamorous and it works: lift weights, sleep, eat enough protein without going to extremes, stay lean and insulin-sensitive, and let IGF-1 settle into a healthy mid-range for your age. If the number is far off in either direction, we look for a cause rather than turning to a drug to move it."

Related at Fishtown Medicine

• Rapamycin for Longevity: What's Proven and What Isn't - the other mTOR-and-growth lever, held to the same evidence standard
• NAD+, NMN, and NR for Longevity - another longevity supplement story where the marketing outruns the data
• Biological Age Testing (DunedinPACE) - measuring the pace of aging, and reading biomarkers in context
• How Much Protein? Muscle, Aging, and Longevity - the protein-and-IGF-1 tension, and why older adults still need more protein
• Early Cancer Detection: A Medicine 3.0 Approach - why a growth signal that raises cancer risk deserves attention to screening
• Peptide Therapy in Philadelphia - how we think about peptides, and where the evidence does and does not support them

Scientific References

1. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. "Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans." Science Translational Medicine. 2011;3(70):70ra13.
2. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. "Dwarf Mice and the Ageing Process." Nature. 1996;384(6604):33.
3. Suh Y, Atzmon G, Cho MO, et al. "Functionally Significant Insulin-Like Growth Factor I Receptor Mutations in Centenarians." Proceedings of the National Academy of Sciences. 2008;105(9):3438-3442.
4. Endogenous Hormones and Breast Cancer Collaborative Group (Key TJ, Appleby PN, Reeves GK, Roddam AW). "Insulin-Like Growth Factor 1 (IGF1), IGF Binding Protein 3 (IGFBP3), and Breast Cancer Risk: Pooled Individual Data Analysis of 17 Prospective Studies." Lancet Oncology. 2010;11(6):530-542.
5. Roddam AW, Allen NE, Appleby P, et al. "Insulin-Like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies." Annals of Internal Medicine. 2008;149(7):461-471.
6. Knuppel A, Fensom GK, Watts EL, et al. "Circulating Insulin-Like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank." Cancer Research. 2020;80(18):4014-4021.
7. Burgers AMG, Biermasz NR, Schoones JW, et al. "Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality." Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2912-2920.
8. Rudman D, Feller AG, Nagraj HS, et al. "Effects of Human Growth Hormone in Men over 60 Years Old." New England Journal of Medicine. 1990;323(1):1-6.
9. Liu H, Bravata DM, Olkin I, et al. "Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly." Annals of Internal Medicine. 2007;146(2):104-115.
10. Levine ME, Suarez JA, Brandhorst S, et al. "Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population." Cell Metabolism. 2014;19(3):407-417.
11. Milman S, Atzmon G, Huffman DM, et al. "Low Insulin-Like Growth Factor-1 Level Predicts Survival in Humans with Exceptional Longevity." Aging Cell. 2014;13(4):769-771.